Transmyocardial laser revascularisation (TMR), a new technique for creating channels in the left ventricular wall to improve blood supply to the damaged heart muscle, offers new hope to those suffering from heart disease. Heart patients who are unfit to undergo a coronary artery bypass graft or percutaneous transluminal coronary angioplasty, can benefit from TMR, which uses high-power CO 2 laser. PLC systems of Cambridge, Massachusetts, US, which has already carried out encouraging tests on over 200 patients with endstage coronary artery disease, is expecting the US Food and Drug Administration's approval to start marketing the laser device.
We are a voice to you; you have been a support to us. Together we build journalism that is independent, credible and fearless. You can further help us by making a donation. This will mean a lot for our ability to bring you news, perspectives and analysis from the ground so that we can make change together.
Comments are moderated and will be published only after the site moderator’s approval. Please use a genuine email ID and provide your name. Selected comments may also be used in the ‘Letters’ section of the Down To Earth print edition.